NITD008 (Synonyms: 7-Deaza-2'-C-acetylene-adenosine)

Name: NITD008
Brand: MedChemExpress
SKU: HY-12957
Rating: 5.0 (7 reviews)

Cat. No.: HY-12957 Purity: 98.04%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

NITD008 is a potent and selective flaviviruse inhibitor which can inhibit Dengue Virus Type 2 (DENV-2) with an EC₅₀ of 0.64 μM. NITD008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

For research use only. We do not sell to patients.

NITD008 Chemical Structure

CAS No. : 1044589-82-3

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 231	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 231	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 210	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 330	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 650	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

7 Publications Citing Use of MCE NITD008

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

EC50: 0.64 μM (DENV-2)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against human A549 cells assessed as intracellular ATP level by Celltiter-Glo luminescent assay Cytotoxicity against human A549 cells assessed as intracellular ATP level by Celltiter-Glo luminescent assay	[PMID: 20457821]
A549	CC₅₀	> 50 μM Compound: NITD008	Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 35306290]
A549	EC₅₀	0.46 μM Compound: NITD008	Antiviral activity against Dengue virus 3 MY22366 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 3 MY22366 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	0.7 μM Compound: NITD008	Antiviral activity against Dengue virus 4 MY22713 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 4 MY22713 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	0.7 μM Compound: 1	Antiviral activity against at 0.3 MOI Dengue virus 2 infected in human A549 cells assessed as level of E protein after 48 hrs by ELISA Antiviral activity against at 0.3 MOI Dengue virus 2 infected in human A549 cells assessed as level of E protein after 48 hrs by ELISA	[PMID: 20457821]
A549	EC₅₀	1.12 μM Compound: NITD008	Antiviral activity against Dengue virus 2 MY10340 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 2 MY10340 infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	1.64 μM Compound: NITD008	Antiviral activity against Dengue virus 2 NGC infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 2 NGC infected in human A549 cells by CFI assay	[PMID: 20516277]
A549	EC₅₀	2.61 μM Compound: NITD008	Antiviral activity against Dengue virus 1 MY10245 infected in human A549 cells by CFI assay Antiviral activity against Dengue virus 1 MY10245 infected in human A549 cells by CFI assay	[PMID: 20516277]
BHK-21	EC₅₀	0.7 μM Compound: 1	Antiviral activity against at 0.3 MOI of Dengue virus 2 infected in hamster BHK21 cells assessed as reduction in viral titer after 48 hrs postinfection Antiviral activity against at 0.3 MOI of Dengue virus 2 infected in hamster BHK21 cells assessed as reduction in viral titer after 48 hrs postinfection	[PMID: 20457821]
HEK293	EC₅₀	9.2 μM Compound: 1	Antiviral activity against Dengue virus 2 infected in human HEK293 cells assessed as level of viral titer after 48 hrs by luciferase reporter gene assay in presence of siRNA targeting adenosine kinase Antiviral activity against Dengue virus 2 infected in human HEK293 cells assessed as level of viral titer after 48 hrs by luciferase reporter gene assay in presence of siRNA targeting adenosine kinase	[PMID: 20457821]
Huh-7	EC₅₀	0.2 μM Compound: NITD-008	Antiviral activity against Zika virus H/PF/2013 infected in human HuH7 cells assessed as reduction in virus replication incubated for 24 hrs by plaque reduction assay Antiviral activity against Zika virus H/PF/2013 infected in human HuH7 cells assessed as reduction in virus replication incubated for 24 hrs by plaque reduction assay	[PMID: 32435384]
Huh-7	EC₅₀	1 μM Compound: NITD-008	Antiviral activity against Dengue virus 2 EDEN 3295 infected in human HuH7 cells assessed as reduction in virus replication incubated for 48 hrs by plaque reduction assay Antiviral activity against Dengue virus 2 EDEN 3295 infected in human HuH7 cells assessed as reduction in virus replication incubated for 48 hrs by plaque reduction assay	[PMID: 32435384]
Huh-7	CC₅₀	100 μM Compound: NITD-008	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescent assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescent assay	[PMID: 33208235]
Huh-7	CC₅₀	100 μM Compound: NITD-008	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter Glo Luminescent assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 48 hrs by CellTiter Glo Luminescent assay	[PMID: 32435384]
PBMC	EC₅₀	0.58 μM Compound: NITD008	Antiviral activity against Dengue virus 2 NGC infected in human PBMC cells by plaque assay Antiviral activity against Dengue virus 2 NGC infected in human PBMC cells by plaque assay	[PMID: 20516277]
RD	CC₅₀	> 20 μM Compound: 3; NITD008	Cytotoxicity against human RD cells assessed as reduction in cell viability by Cell Titer-Glo luminescent cell viability assay Cytotoxicity against human RD cells assessed as reduction in cell viability by Cell Titer-Glo luminescent cell viability assay	[PMID: 34560428]
RD	CC₅₀	> 20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with EV71 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with EV71 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
RD	CC₅₀	> 20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with CA6 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with CA6 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
RD	CC₅₀	> 20 μM Compound: 4; NITD008	Cytotoxicity against human RD cells infected with CA16 incubated for 3 days by CellTiter 96 luminescent cell viability assay Cytotoxicity against human RD cells infected with CA16 incubated for 3 days by CellTiter 96 luminescent cell viability assay	[PMID: 35598412]
Vero	CC₅₀	> 100 μM Compound: NITD008	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability treated for 3 days measured on day 4 by cell titer-blue fluorescent assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability treated for 3 days measured on day 4 by cell titer-blue fluorescent assay	[PMID: 26774922]
Vero	EC₅₀	0.03 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 4 Martinique 017 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 4 Martinique 017 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.08 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 4 Dakar HD34460 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 4 Dakar HD34460 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.12 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 3 Bolivia 4025 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 3 Bolivia 4025 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.67 μM Compound: NITD008	Antiviral activity against EV71 infected in African green monkey Vero cells after 48 hrs by plaque assay Antiviral activity against EV71 infected in African green monkey Vero cells after 48 hrs by plaque assay	[PMID: 27776325]
Vero	EC₅₀	0.82 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 2 Martinique H/IMTSSA-MART/98-703 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 2 Martinique H/IMTSSA-MART/98-703 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	EC₅₀	0.86 μM Compound: NITD008	Antiviral activity against clinical isolates of Dengue virus 1 Indonesia JKT 1186 TVP 949 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method Antiviral activity against clinical isolates of Dengue virus 1 Indonesia JKT 1186 TVP 949 infected in African green monkey Vero E6 cells assessed as reduction in viral RNA after 4 days by qRT-PCR method	[PMID: 26774922]
Vero	CC₅₀	119.97 μM Compound: NITD008	Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against African green monkey Vero cells after 48 hrs by MTT assay	[PMID: 27776325]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity by measuring viral RNA by RT-qPCR method	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay Inhibition of RNA-dependent RNA polymerase in Zika virus GZ01/2016 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay	[PMID: 31549836]
Vero	EC₅₀	137 nM Compound: 3; NITD008	Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay Inhibition of RNA-dependent RNA polymerase in Zika virus FSS13025/2010 infected in African green monkey Vero cells assessed as antiviral activity measured 48 hrs post infection by plaque assay	[PMID: 31549836]
Vero	CC₅₀	74 μM Compound: NITD008	Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by DAPI staining based assay Cytotoxicity against African green monkey Vero cells incubated for 48 hrs by DAPI staining based assay	[PMID: 36596229]

In Vitro

NITD008 potently inhibits other, including Dengue virus (DENV), West Nile virus, yellow fever virus, and Poissan virus. NITD008 inhibits DENV-2 in a dose-responsive manner, with an EC₅₀ value of 0.64 μM; treatment with 9 μM compound reduces viral titer by >104-fold^[1]. NITD008 also inhibits a luciferase-reporting replicon of hepatitis C virus (HCV, genotype 1b), a member from the genus Hepacivirus, with an EC₅₀ value of 0.11 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NITD008 is orally bioavailable and has good pharmacokinetic properties. NITD008 exhibits the best pharmacokinetic parameters when formulated using 6 N of HCl (1.5 equimolar amount), 1 N of NaOH (pH adjusted to 3.5), and 100 mM citrate buffer (pH 3.5). Following i.v. injection, NITD008 has a high volume of distribution (3.71 L/kg) and a low systemic clearance (31.11 mL/min per kg), resulting in a long elimination half-life (t_1/2=4.99 h). After p.o. dosing, NITD008 is rapidly absorbed (time of peak plasma concentration=0.5 h), with a maximal plasma concentration of 3 μM and bioavailability of 48%. Treatment of the mice immediately after viral infection with 1 mg/kg of NITD008 does not reduce mortality, but treatment with 3 mg/kg partially protects and treatment with ≥10 mg/kg completely protects the infected mice from death. NITD008 can suppress peak viremia, decrease cytokine elevation, and prevent death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

290.27

Formula

C₁₃H₁₄N₄O₄

CAS No.

1044589-82-3

Appearance

Solid

Color

White to gray

SMILES

O[C@@]1(C#C)[C@H](N2C=CC3=C(N)N=CN=C32)O[C@H](CO)[C@H]1O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 50 mg/mL (172.25 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4451 mL	17.2253 mL	34.4507 mL
5 mM	0.6890 mL	3.4451 mL	6.8901 mL
10 mM	0.3445 mL	1.7225 mL	3.4451 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.61 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.04%

Select Batch:

Data Sheet (285 KB) SDS (252 KB)

COA (258 KB) HNMR (282 KB) RP-HPLC (227 KB) MS (197 KB)

Handling Instructions (2659 KB)

References

[1]. Yin Z, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. [Content Brief]

Cell Assay ^[1]	For measurement of compound cytotoxicity, Vero cells (10000 cells per well of a 96-well plate) are incubated with various concentrations of NITD008 (3, 6, 12, 25, 50 μM) for 48 h; cell viability is quantified using a MTT assay^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Mice^[1] The in vivo efficacy of NITD008 is evaluated in a dengue viremia model and a lethal model in mice. Both models use AG129 mice (with knockout IFN-α/β and IFN-γ receptors). DENV-2 strains TSV01and D2S10, respectively, are used in the 2 models and are propagated in C6/36 mosquito cells grown in RPMI-1640 medium with 5% FBS (vol/vol) at 28°C. The evaluation in the lethal model is performed by injecting mice i.v. with 0.2 mL of RPMI-1640 medium containing 3×10⁷ pfu/mL DENV-2 strain D2S10; the infected mice are then subjected to different treatment regimens, as indicated in each experiment. NITD008 (1, 3, 10, 25, 50 mg/kg) in 0.2-0.25 mL of formulation solution is administered by p.o. gavage. The mice (6 or 8 mice per group) are monitored twice a day^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Yin Z, et al. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.4451 mL	17.2253 mL	34.4507 mL	86.1267 mL
	5 mM	0.6890 mL	3.4451 mL	6.8901 mL	17.2253 mL
	10 mM	0.3445 mL	1.7225 mL	3.4451 mL	8.6127 mL
	15 mM	0.2297 mL	1.1484 mL	2.2967 mL	5.7418 mL
	20 mM	0.1723 mL	0.8613 mL	1.7225 mL	4.3063 mL
	25 mM	0.1378 mL	0.6890 mL	1.3780 mL	3.4451 mL
	30 mM	0.1148 mL	0.5742 mL	1.1484 mL	2.8709 mL
	40 mM	0.0861 mL	0.4306 mL	0.8613 mL	2.1532 mL
	50 mM	0.0689 mL	0.3445 mL	0.6890 mL	1.7225 mL
	60 mM	0.0574 mL	0.2871 mL	0.5742 mL	1.4354 mL
	80 mM	0.0431 mL	0.2153 mL	0.4306 mL	1.0766 mL
	100 mM	0.0345 mL	0.1723 mL	0.3445 mL	0.8613 mL

NITD008 Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NITD0081044589-82-37-Deaza-2'-C-acetylene-adenosineNITD 008NITD-008Dengue virusFlavivirusDNA/RNA SynthesisDENVInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

NITD008 (Synonyms: 7-Deaza-2'-C-acetylene-adenosine)

Customer Review

NITD008 Related Antibodies

7 Publications Citing Use of MCE NITD008

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

NITD008 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NITD008 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report